Investigators collected epidemiological, demographic, clinical, laboratory, radiological and occupation information, along with contact history, of 671 patients with laboratory-confirmed COVID-19 reported from January 23 to February 5, 2020, in Henan province, China.
[International Journal of Epidemiology]
[zotpress userid=’6445212′ items=’C5P3D2MF’ style=’apa’ cite=’yes’]
Vaxart, Inc. announced that its oral COVID-19 vaccine has been selected to participate in a non-human primate challenge study, organized and funded by Operation Warp Speed, a new national program aiming to provide substantial quantities of safe, effective vaccine for Americans by January 2021.
[Vaxart, Inc. ]
Fulcrum Therapeutics, Inc. announced that it received early notification from the US FDA that the company may proceed with initiating a Phase III, randomized, double-blind, placebo-controlled trial of losmapimod in higher risk hospitalized adults with COVID-19. Losmapimod is an orally available selective p38α/β mitogen activated protein kinase inhibitor.
[Fulcrum Therapeutics, Inc.]
On 24 June, the US National Institutes of Health (NIH) described the actions it will take when alerted to reports of unsafe behavior, including restricting scientists from peer-review panels, holding back pending grants and refusing university requests to transfer funding to other institutions in cases where a harasser changes jobs.
The concomitant activation of ferroptosis and autophagy by 15-lipoxygenase-1–PE-binding protein-1 complexes and their hydroperoxy-phospholipids revealed a pathobiologic pathway relevant to asthma and amenable to therapeutic targeting.
[Proceedings of the National Academy of Sciences of the United States of America]
[zotpress userid=’1254621′ items=’DUI9KEUP’ style=’apa’ cite=’yes’]
The authors focus on the complex crosstalk between miRNAs and ROS in diseases of the cardiac and pulmonary compartments.
[International Journal of Molecular Sciences]
[zotpress userid=’1254621′ items=’3SWRAZUB’ style=’apa’ cite=’yes’]
The study is expected to enroll 30 patients at up to 10 centers in the US and the company expects to have the majority of centers enrolling within the coming weeks.
Achilles Therapeutics announced that it has dosed the first patient in a Phase I/II CHIRON study of a clonal neoantigen T cell therapy in patients with advanced non-small cell lung cancer.
[Achilles Therapeutics (GlobeNewswire, Inc.)]
Investigators demonstrated that potent and selective ubiquitin carboxy-terminal hydrolase L1 (UCHL1) inhibitors blocked pro-fibrotic responses in a cellular model of idiopathic pulmonary fibrosis, supporting the potential of UCHL1 as a potential therapeutic target in fibrotic diseases.
[Journal of the American Chemical Society]
[zotpress userid=’6552324′ items=’SL9737E5′ style=’apa’ cite=’yes’]
investigated the mechanism by which 4‐FPAC induced cytotoxicity and arrested the progression of cell cycle as well as metastasis in A549.
[Journal of Biochemical and Molecular Toxicology]
[zotpress userid=’1254621′ items=’CX8YULJE’ style=’apa’ cite=’yes’]
Binding of V(V) or V(IV) to transferrin in cell culture medium drastically reduced its cellular uptake and antiproliferative activity in the A549 cell line that expresses transferrin receptor 1.
[zotpress userid=’1254621′ items=’BF4ZYIZ6′ style=’apa’ cite=’yes’]